The endoscopy company expects target market segment to continue growing at rapid rate.
The software is targeted specifically at prostate cancer.
Company gets the new year rolling with trial to treat uncontrolled hypertension.
Reports are trickling out of unexpected effects of excise tax.
Appointee also will serve on the board.
The implants are intended to treat chronic back and leg pain.
After an unsatisfactory close to 2012, company trims the fat.
Please visit our sister sites:
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.